Avatrombopag

Last updated

Avatrombopag
Avatrombopag.svg
Clinical data
Pronunciationa" va trom' boe pag
Trade names Doptelet
AHFS/Drugs.com Monograph
MedlinePlus a618032
License data
Pregnancy
category
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
  • 1-[3-Chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C29H34Cl2N6O3S2
Molar mass 649.65 g·mol−1
3D model (JSmol)
  • C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl
  • InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38) Yes check.svgY
  • Key:OFZJKCQENFPZBH-UHFFFAOYSA-N
 X mark.svgNYes check.svgY  (what is this?)

Avatrombopag, sold under the brand name Doptelet, is a medication that is used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure. [8] [9] It was approved for medical use in the United States in May 2018, [10] [11] the European Union in June 2019, [7] and Australia in January 2023. [1]

It acts as a thrombopoietin receptor agonist. [12]

References

  1. 1 2 3 "Doptelet". Therapeutic Goods Administration (TGA). 30 January 2023. Archived from the original on 5 February 2023. Retrieved 8 April 2023.
  2. ↑ "Doptelet (Swedish Orphan Biovitrum Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 27 March 2023. Retrieved 8 April 2023.
  3. ↑ "AusPAR: Doptelet". Therapeutic Goods Administration (TGA). 8 February 2024. Retrieved 31 March 2024.
  4. ↑ "Details for: Doptelet". Health Canada . 22 January 2024. Archived from the original on 3 March 2024. Retrieved 3 March 2024.
  5. ↑ "Summary Basis of Decision for Doptelet". Health Canada . 17 May 2024. Retrieved 8 June 2024.
  6. ↑ "Doptelet- avatrombopag maleate tablet, film coated". DailyMed. 1 July 2021. Archived from the original on 3 March 2024. Retrieved 3 March 2024.
  7. 1 2 "Doptelet EPAR". European Medicines Agency (EMA). 24 April 2019. Archived from the original on 22 May 2020. Retrieved 2 May 2020.
  8. ↑ Abdela J (2019). "Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag". Clinical Medicine Insights. Blood Disorders. 12 1179545X19875105. doi:10.1177/1179545X19875105. PMC   6804364 . PMID   31673229.
  9. ↑ Markham A (November 2021). "Avatrombopag: A Review in Thrombocytopenia". Drugs. 81 (16): 1905–1913. doi:10.1007/s40265-021-01613-y. PMC   8610948 . PMID   34709601.
  10. ↑ "FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure". U.S. Food and Drug Administration (FDA) (Press release). 21 May 2018. Archived from the original on 11 December 2019. Retrieved 2 May 2020.
  11. ↑ "Drug Approval Package: Doptelet (avatrombopag)". U.S. Food and Drug Administration (FDA). 28 June 2018. Archived from the original on 7 April 2021. Retrieved 2 May 2020.
  12. ↑ Kuter DJ (November 2021). "The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag". Blood Reviews. 53 100909. doi: 10.1016/j.blre.2021.100909 . PMID   34815110. S2CID   244285488.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.